A phase IV multicenter study of the efficacy and safety of 48-week induction treatment with TRIZIVIR (abacavir 300 mg/lamivudine 150mg/zidovudine 300mg [lamivudine/zidovudine/abacavir] combination tablet BID [twice daily]) with efavirenz (600mg QD [daily]) followed by 48-week randomized, open-label, maintenance treatment with TRIZIVIR with or without efavirenz in HIV-1 infected antiretroviral therapy naive subjects

Trial Profile

A phase IV multicenter study of the efficacy and safety of 48-week induction treatment with TRIZIVIR (abacavir 300 mg/lamivudine 150mg/zidovudine 300mg [lamivudine/zidovudine/abacavir] combination tablet BID [twice daily]) with efavirenz (600mg QD [daily]) followed by 48-week randomized, open-label, maintenance treatment with TRIZIVIR with or without efavirenz in HIV-1 infected antiretroviral therapy naive subjects

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2005

At a glance

  • Drugs Efavirenz; Lamivudine/zidovudine/abacavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top